Genascence’s $10.5 Million Series A Financing

Latham & Watkins advised Genascence in the transaction.

Genascence Corporation (Genascence), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, has completed the first closing in a Series A financing led by Pacira BioSciences, Inc., totaling US$10.5 million. Additional investors included Polymerase Capital, DeepWork Capital, and University of Florida Research Foundation. 

Latham & Watkins advised Genascence in the funding round with a deal team led by Bay Area partners Ben Potter (Picture) and Judith Hasko, with Century City associate Simon Moshkovich.

Involved fees earner: Judith Hasko – Latham & Watkins; Simon Moshkovich – Latham & Watkins; Benjamin Potter – Latham & Watkins;

Law Firms: Latham & Watkins;

Clients: Genascence;